background
background
hero avatar

NEWS

Akston Biosciences and Biolexis Collaborate to Launch a COVID-19 Vaccine in 130+ Countries

Covid-19 protein subunit vaccine – AKS-452

Transportable without cold-chain:

Shelf-stable for over six months at 25° Celsius (77° Fahrenheit)

Maintains potency for one month at 37° Celsius (99° Fahrenheit)

High volume, low cost manufacturing:

Uses established antibody production infrastructure

Single production line can make over one billion doses per year

Does not include mRNA technology, viral vectors, or a weakened SARS-CoV-2 virus

Focused presentation of Receptor Binding Domain (RBD)

Designed to preserve effectiveness against viral variants

Suitable for boosting immune response of those vaccinated or recovered from infection